Helix BioPharma Corp.

TSX:HBP.TO

Biotechnology

Healthcare
$0.86 -4.70%

-$0.07 today

Market cap
$65.69M
Beta
-0.29
P/E (TTM)
-32.6
EPS (TTM)
-$0.04
52W Low $0.84High $5.40

Volume 0.00M

Average 0.00M

HBP.TO Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Helix BioPharma Corp.TSX: HBP.TO

Operating Income · Q3 FY2026 · quarter ended Apr 2026

Operating income remains negative

Q3 FY2026 operating income was -CA$690K, compared with -CA$1.55M a year earlier. Trailing-twelve-month operating income was -CA$3.3M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether next quarter's operating income reaches the consensus estimate of CA$0, a +100.0% change from the same quarter last year.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-CA$690K-1.2% QoQ
Last fiscal yearJul 2025
-CA$5.43M+42.1% YoY
LTMApr 2026
-CA$3.3M+66.1% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+55.6%+100.0%+44.4 pp
1 year+42.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

CAD · from the income statement

Latest · FY2025
(5.43M) CAD
Year-over-year change
+42.1%

Operating Income vs competitors

How HBP.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +66.1% is the 2nd highest of 4, against a peer median of +51.1%.
HBP.TO Competitors
Operating Income for HBP.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HBP.TOHelix BioPharma Corp.LTM Apr 2026-CA$3.3M CAD+66.1%——
HLS.TOHLS Therapeutics Inc.LTM Mar 2026-$4.09M USD+66.4%—7.3%
SVA.TOSernova Corp.LTM Apr 2026-CA$10.28M CAD+51.1%——
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026-$30.06M USD———
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026-CA$35.59M CAD+11.7%——
Peer median (excluding HBP.TO) —+51.1%—7.3%

Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Revenue00000
Cost of Revenue173K12K13K14K10K
Gross Profit(173K)(12K)(13K)(14K)(10K)
Gross Margin—————
Research & Development5.88M4.54M5.28M6.1M3.58M
Selling, General & Admin3.25M595K299K3.26M1.84M
Operating Expenses9.13M6.04M6.33M9.36M5.42M
Depreciation & Amortization173K12K13K14K10K
EBITDA(9.46M)(6.03M)(6.31M)(9.38M)(5.21M)
EBITDA Margin—————
Operating Income(9.61M)(6.54M)(6.28M)(9.37M)(5.43M)
Operating Margin—————
Interest Income154K47K31K17K
Interest Expense15K18K14K7K10K
Other Income / Expenses(443K)(523K)36K(25K)192K
Income Before Tax(9.57M)(6.56M)(6.29M)(9.4M)(5.23M)
Pre-Tax Margin—————
Income Tax Expense(1.66M)(484K)14K(132K)(28K)
Net Income(7.91M)(6.08M)(6.29M)(9.26M)(5.21M)
Net Margin—————
EPS (Basic)(0.29)(0.20)(0.16)(0.21)(0.09)
EPS (Diluted)(0.29)(0.20)(0.16)(0.21)(0.09)
Weighted Avg Shares27.58M29.9M38.65M44.49M55.74M
Weighted Avg Shares (Diluted)27.58M29.9M38.65M44.49M55.74M

Helix BioPharma Corp.

TSX:HBP.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.